Funding for this research was provided by:
Division of Cancer Epidemiology and Genetics, National Cancer Institute (1U01CA215547)
Breast Cancer Research Foundation (BCRF)
Received: 5 October 2020
Accepted: 17 January 2021
First Online: 4 February 2021
Ethics approval and consent to participate
: This study involved human subjects research and was carried out in compliance with the Helsinki Declaration with review and oversight from the Institutional Review Board of MD Anderson Cancer Center (protocol LAB08–0824). The need for informed consent from human subjects specifically for the use of their samples for this research was waived by based on the new and revised Exemption categories (45CFR 46.104), meeting Exemption Category 4(ii): Information, which may include information about biospecimens, is recorded by the investigator in such a manner that the identity of the human subjects cannot readily be ascertained directly or through identifiers linked to the subjects, the investigator does not contact the subjects, and the investigator will not re-identify subjects. Institutional Review Board of MD Anderson Cancer Center approved the waiver of consent.
: Not applicable.
: Disclosures related to this study: WFS, BVS, CH, CF and RL are co-inventors on patent WO2017189976A1 “Targeted measure of transcriptional activity related to hormone receptors”. WFS, CF and RL own shares of Delphi Diagnostics, without employment or administrative position. Disclosures unrelated to this study: WFS owns shares of IONIS Pharmaceuticals. TP is a paid consultant and owns shares in Delphi Diagnostics. CH is currently an employee of Bristol-Myers Squibb. LP has received consulting fees and honoraria from Astra Zeneca, Merck, Novartis, Genentech, Eisai, Pieris, Immunomedics, Seattle Genetics, Almac, Biotheranostics and Syndax.